Tailor-made antibody therapeutics

被引：45

作者：

Chowdhury, PS ^{[1
]}

Wu, H ^{[1
]}

机构：

[1] Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA

来源：

METHODS | 2005年 / 36卷 / 01期

关键词：

therapeutic antibodies; antibody engineering; affinity maturation; effector functions; FcRn binding; antibody fragments; immunoconjugates; immunotoxins; immunocytokines; ADEPT; radio-labeled antibodies; Bi-specific antibodies; PEGylation;

D O I：

10.1016/j.ymeth.2005.01.002

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 18 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, scientists have gone beyond the traditional antibody molecules. Antibodies have been engineered in a variety of ways to meet the challenges posed by different biological settings. Described in this review is an abridged account of the different ways antibodies have been tailored to make them efficient drug molecules. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：11 / 24

页数：14

共 97 条

[1]

Adams GP, 2001, CANCER RES, V61, P4750

[2]

Adams GP, 1998, CANCER RES, V58, P485

[3]

ADAMS GP, 1993, CANCER RES, V53, P4026

[4] IN-VITRO EVOLUTION OF A NEUTRALIZING HUMAN-ANTIBODY TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO ENHANCE AFFINITY AND BROADEN STRAIN CROSS-REACTIVITY [J].

BARBAS, CF ;

HU, D ;

DUNLOP, N ;

SAWYER, L ;

CABABA, D ;

HENDRY, RM ;

NARA, PL ;

BURTON, DR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3809-3813

[5] TRANSPORT OF FLUID AND MACROMOLECULES IN TUMORS .3. ROLE OF BINDING AND METABOLISM [J].

BAXTER, LT ;

JAIN, RK .

MICROVASCULAR RESEARCH, 1991, 41 (01) :5-23

[6] Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library [J].

Begent, RHJ ;

Verhaar, MJ ;

Chester, KA ;

Casey, JL ;

Green, AJ ;

Napier, MP ;

HopeStone, LD ;

Cushen, N ;

Keep, PA ;

Johnson, CJ ;

Hawkins, RE ;

Hilson, AJW ;

Robson, L .

NATURE MEDICINE, 1996, 2 (09) :979-984

[7] A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2 [J].

Bera, TK ;

Onda, M ;

Brinkmann, U ;

Pastan, I .

JOURNAL OF MOLECULAR BIOLOGY, 1998, 281 (03) :475-483

[8] SINGLE-CHAIN ANTIGEN-BINDING PROTEINS [J].

BIRD, RE ;

HARDMAN, KD ;

JACOBSON, JW ;

JOHNSON, S ;

KAUFMAN, BM ;

LEE, SM ;

LEE, T ;

POPE, SH ;

RIORDAN, GS ;

WHITLOW, M .

SCIENCE, 1988, 242 (4877) :423-426

[9] A RECOMBINANT IMMUNOTOXIN CONTAINING A DISULFIDE-STABILIZED FV FRAGMENT [J].

BRINKMANN, U ;

REITER, Y ;

JUNG, SH ;

LEE, B ;

PASTAN, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7538-7542

[10] TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity [J].

Chames, P ;

Willemsen, RA ;

Rojas, G ;

Dieckmann, D ;

Rem, L ;

Schuler, G ;

Bolhuis, RL ;

Hoogenboom, HR .

JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :1110-1118

← 1 2 3 4 5 6 7 8 9 10 →